81882-62-4

Usage

Uses

Used in Pharmaceutical Research:
3-amino-N-(isopropyl)benzamide is used as a research compound for exploring its potential biological activities and therapeutic effects. Its unique structure allows scientists to investigate its interactions with biological targets, which may lead to the development of new drugs or therapeutic agents.
Used in Organic Synthesis:
In the field of organic chemistry, 3-amino-N-(isopropyl)benzamide serves as a key intermediate in the synthesis of various complex organic molecules. Its versatile structure enables chemists to modify and functionalize it for the creation of new compounds with specific properties and applications.
Used in Chemical Research:
3-amino-N-(isopropyl)benzamide is employed as a model compound in chemical research to study reaction mechanisms, synthetic routes, and the properties of benzamides. This helps in understanding the reactivity and behavior of similar compounds and contributes to the advancement of organic chemistry.
Used in Material Science:
3-amino-N-(isopropyl)benzamide may find applications in material science, where its unique structure and properties can be exploited to develop new materials with specific characteristics. For instance, it could be used in the design of organic electronic devices, sensors, or other advanced materials.

InChI:InChI=1/C10H14N2O/c1-7(2)12-10(13)8-4-3-5-9(11)6-8/h3-7H,11H2,1-2H3,(H,12,13)

Upstream product

• 121-90-4 m-nitrobenzoic acid chloride 
• 121-92-6 3-nitrobenzoic acid 
• 50445-53-9 N-isopropyl-3-nitrobenzamide 
• 99-05-8 meta-aminobenzoic acid 
• 75-31-0 isopropylamine 

Downstream Products

• 1219731-48-2 N-isopropyl-3-(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ureido)benzamide 
• 1219727-31-7 3-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)-N-isopropylbenzamide 
• 1219727-43-1 3-(3-(2-(2-(dimethylamino)ethoxy)-4-(5-methyl-7H-pyrrolo-[2,3-d]pyrimidin-4-yl)phenyl)ureido)-N-isopropylbenzamide 
• 1219727-46-4 3-(3-(2-fluoro-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-phenyl)ureido)-N-isopropylbenzamide 
• 1219727-45-3 N-isopropyl-3-(3-(4-(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)benzamide 
• 1219727-38-4 N-isopropyl-3-(3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)benzamide 
• 1219727-41-9 N-isopropyl-4-[3-[4-(9H-purin-6-yl)phenyl]ureido]-benzamide 
• 1219727-40-8 4-[3-[4-(7-ethyl-8-oxo-8,9-dihydro-7H-purin-6-yl)phenyl]-ureido]-N-isopropylbenzamide 
• 1219727-39-5 N-isopropyl-4-[3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-ureido]benzamide 
• 1361414-23-4 3-(3-(4-(2-aminopyrimidin-4-yl)phenyl)ureido)-N-isopropylbenzamide 
• 1219727-30-6 N-isopropyl-3-(3-(4-(pyridin-4-yl)phenyl)ureido)benzamide 
• 1219727-28-2 3-(3-(4-(1H-pyrazol-4-yl)phenyl)ureido)-N-isopropylbenzamide 

Relevant academic research and scientific papers

Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor

Bromodomain and PHD finger containing protein transcription factor (BPTF) is an epigenetic protein involved in chromatin remodelling and is a potential anticancer target. The BPTF bromodomain has one reported small molecule inhibitor (AU1, rac-1). Here, advances made on the structure-activity relationship of a BPTF bromodomain ligand are reported using a combination of experimental and molecular dynamics simulations leading to the active enatiomer (S)-1. Additionally, a ligand deconstruction analysis was conducted to characterize important pharmacophores for engaging the BPTF bromodomain. These studies have been enabled by a protein-based fluorine NMR approach, highlighting the versatility of the method for selectivity, ligand deconstruction, and ligand binding. To enable future analysis of biological activity, cell growth analyses in a panel of cancer cell lines were carried out using CRISPR-Cas9 and (S)-1 to identify cell-based model systems that are sensitive to BPTF inhibition.

Adamantane styrene derivatives, and preparation method and application thereof

The invention discloses adamantane styrene derivatives and analysis of the biological activity of the adamantane styrene derivatives. According to the invention, a synthesized compound retains an adamantane structure, an adamantane ring structure is conne

LIM KINASE INHIBITORS

A dynamic actin cytoskeleton is necessary for viral entry, intracellular migration, and virion release. For the human immunodeficiency virus (HIV), during viral entry, the virus triggers early actin activity through hijacking chemokine coreceptor signalin

Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors

The discovery/optimization of bis-aryl ureas as Limk inhibitors to obtain high potency and selectivity and appropriate pharmacokinetic properties through systematic SAR studies is reported. Docking studies supported the observed SAR. Optimized Limk inhibitors had high biochemical potency (IC50 400-fold), potent inhibition of cofilin phosphorylation in A7r5, PC-3, and CEM-SS T cells (IC50 1 μM), and good in vitro and in vivo pharmacokinetic properties. In the profiling against a panel of 61 kinases, compound 18b at 1 μM inhibited only Limk1 and STK16 with ≥80% inhibition. Compounds 18b and 18f were highly efficient in inhibiting cell-invasion/migration in PC-3 cells. In addition, compound 18w was demonstrated to be effective on reducing intraocular pressure (IOP) on rat eyes. Taken together, these data demonstrated that we had developed a novel class of bis-aryl urea derived potent and selective Limk inhibitors.

Synthesis and structure-activity relationship of (E)-phenoxyacrylic amide derivatives as Hypoxia-Inducible Factor (HIF) 1α inhibitors

A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) 1α inhibitors. The present structure-activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1α under hypoxic conditions (IC50 = 0.12 μM in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1α accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-1α inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.

UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS

The invention is directed to compounds that can inhibit the bioactivity of one or more kinases such as any of Rho kinases, PKB (Akt) kinases, p70S6K kinase, LIM kinases, or IKK kinases, to methods of use of those compounds, and to methods of preparation of those compounds The inventive compounds can be used In the treatment of a variety of medical malconditions.